Technology Networks reports research tying GLP-1 drugs to improved kidney results in bipolar disorder patients.
Recap by typeshit. Full story at Technology Networks.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
A new GLP-1 described as stronger than current options is being tested in trials, and researchers lay out what people should understand about it.
A SURPASS-4 analysis at ASN Kidney Week 2026 found rapid kidney decline in 5% on tirzepatide versus 13% on insulin glargine, with the biggest gains in high protein groups.
Among 208,970 matched adults with type 2 diabetes, GLP-1 starters had 0.15% new diagnoses versus 0.10% on DPP-4 drugs. Authors call it a signal needing confirmation.
Reuters looks at influencers pushing dietary supplements to people on weight loss drugs, turning TikTok into a sales engine for so-called GLP-1 products.
GoodRx says approved peptides went through safety and effectiveness testing, while wellness peptides sold without approval lack that evidence and carry risks.
Loading…